Journals / Turkish Journal of Hematology / 2019 / Cilt: 36 - Sayı: 1

Investigation of the Relationship Between Fok1 and Col1A1 Gene Polymorphisms and Development of Treatment-Related Bone Complications in Children with Acute Lymphoblastic Leukemia

Akut Lenfoblastik Lösemili Çocuklarda Fok1 ve Col1A1 Gen Polimorfizmleri ile Tedaviye Bağlı Kemik Komplikasyonlarının Gelişimi Arasındaki İlişkinin Araştırılması

Pages
12–18
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The association between Col1A1 Sp1-binding site genepolymorphisms and osteonecrosis has to be assessed in a larger groupof ALL survivors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In acute lymphoblastic leukemia (ALL), various clinical riskfactors and genetic predispositions contribute to the developmentof bone complications during and after chemotherapy.
📊
Key Findings & Data:In this study,we aimed to investigate whether vitamin D receptor (VDR) Fok1 andcollagen protein Col1A1 Sp1-binding site gene polymorphisms, whichare important in bone mineral and matrix formation, have effects onthe development of bone abnormalities in childhood ALL survivors.Materials and Methods: Fifty children with ALL who were treated withthe ALL Berlin-Frankfurt-Muenster-95 protocol between 1998 and 2008and were followed for at least 7 years were enrolled.
💡
Conclusion & Impact:The association between Col1A1 Sp1-binding site genepolymorphisms and osteonecrosis has to be assessed in a larger groupof ALL survivors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In acute lymphoblastic leukemia (ALL), various clinical riskfactors and genetic predispositions contribute to the developmentof bone complications during and after chemotherapy. In this study,we aimed to investigate whether vitamin D receptor (VDR) Fok1 andcollagen protein Col1A1 Sp1-binding site gene polymorphisms, whichare important in bone mineral and matrix formation, have effects onthe development of bone abnormalities in childhood ALL survivors.Materials and Methods: Fifty children with ALL who were treated withthe ALL Berlin-Frankfurt-Muenster-95 protocol between 1998 and 2008and were followed for at least 7 years were enrolled. The control groupconsisted of 96 healthy children. VDR Fok1 and Col1A1 Sp1-bindingsite gene polymorphisms were analyzed by polymerase chain reactionand restriction fragment length polymorphism. Bone mineral density(BMD) and markers of bone metabolism were all noted. All patients whopresented with pain in the joints were examined for bone pathologieswhile on chemotherapy or during long-term follow-up.Results: Low BMD (16%), osteoporosis (12%), and osteonecrosis(8%) were present in a total of 18 patients (36%). The frequency ofosteonecrosis and total bone abnormalities was significantly higherin children aged ≥10 years (p=0.001). The risk of low BMD andosteonecrosis was higher in those with vitamin D deficiency. Only theCol1A1 Sp1-binding site gene polymorphism showed a significantassociation in ALL patients with osteonecrosis.Conclusion: The development of therapy-induced bone mineralloss and osteonecrosis in children with ALL is frequent and the riskis especially higher in children aged ≥10 years and with vitamin Ddeficiency. The association between Col1A1 Sp1-binding site genepolymorphisms and osteonecrosis has to be assessed in a larger groupof ALL survivors.

Özet

Amaç: Akut lenfoblastik lösemide (ALL), çeşitli klinik risk faktörleri ve genetik yatkınlıklar kemoterapi sırasında ve sonrasında kemik komplikasyonlarının gelişmesine katkıda bulunur. Bu çalışmada, kemik mineral ve matriks oluşumunda önemli olan D vitamini reseptörü (VDR) Fok1 ve kollajen proteini Col1A1 Sp1 bağlayıcı bölge gen polimorfizmlerinin, ALL’den sağ kalan çocuklarda kemik anormalliklerinin gelişimine etkilerinin olup olmadığını araştırmayı amaçladık. Gereç ve Yöntemler: 1998-2008 yılları arasında ALL tanısı alıp, ALL Berlin-Frankfurt-Muenster-95 protokolü ile tedavi edilen ve en az 7 yıl takip edilen 50 çocuk çalışmaya dahil edildi. Kontrol grubu 96 sağlıklı çocuktan oluşuyordu. VDR Fok1 ve Col1A1 Sp1 bağlayıcı bölge gen polimorfizmleri polimeraz zincir reaksiyonu ve restriksiyon fragman uzunluğu polimorfizmi ile analiz edildi. Kemik mineral yoğunluğu (KMY) ve kemik metabolizması belirteçleri kaydedildi. Eklemlerde ağrı ile başvuran tüm hastalar kemoterapi veya uzun süreli takip sırasında kemik patolojileri açısından incelendi. Bulgular: Toplam 18 hastada (%36) düşük KMY (%16), osteoporoz (%12) ve osteonekroz (%8) mevcuttu. Osteonekroz sıklığı ve toplam kemik anormallikleri 10 yaş ve üstü çocuklarda anlamlı olarak yüksek bulundu (p=0,001). D vitamini eksikliği olanlarda düşük BMD ve osteonekroz riski daha yüksekti. Gen polimorfizmleri ile ilişki incelendiğinde; sadece Col1A1 Sp1 bağlayıcı bölge gen polimorfizmi ile osteonekroz arasında anlamlı bir ilişki gösterilmiştir. Sonuç: Sonuç olarak, ALL’den sağ kalan çocuklarda tedaviye bağlı kemik mineral kaybı ve osteonekroz gelişimi sıktır ve bu risk özellikle 10 yaş ve üstü D vitamini eksikliği olan çocuklarda daha yüksektir. Col1A1 Sp1 bağlanma bölgesi gen polimorfizmleri ve osteonekroz arasındaki ilişkiyi araştırmak için ALL’den sağ kalan bireyler üzerinde yapılacak daha geniş çaplı çalışmalara ihtiyaç vardır.

🔖

Cite This Article

KIZILDAĞ, S., ERDEM, M., TÜFEKÇİ, Ö., YILMAZ, Ş., KIZMAZOĞLU, D., FİLİBELİ, B. E., ÖREN, H. (2022). Investigation of the Relationship Between Fok1 and Col1A1 Gene Polymorphisms and Development of Treatment-Related Bone Complications in Children with Acute Lymphoblastic Leukemia. Turkish Journal of Hematology, Cilt: 36 - Sayı: 1, 12–18. https://ajindex.com/articles/606707

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Schrappe M, Möricke A, Reiter A, Henze G, Welte K, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Gruhn B, Niemeyer C, Kremens B, Niggli F, Debatin KM, Ratei R, Stanulla M, Beier R, Cario G, Schrauder A, Zimmermann M. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL BFM study group from 1981 to 2000. Klin Padiatr 2013;225(Suppl 1):62-72
  2. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, Aricò M, Zimmermann M, Mann G, De Rossi G, Stanulla M, Locatelli F, Basso G, Niggli F, Barisone E, Henze G, Ludwig WD, Haas OA, Cazzaniga G, Koehler R, Silvestri D, Bradtke J, Parasole R, Beier R, van Dongen JJ, Biondi A, Schrappe M. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP BFM ALL 2000 study. Blood 2010;115:3206-3214
  3. Haddy TB, Mosher RB, Reaman GH. Late effects in long-term survivors after treatment for childhood acute leukemia. Clin Pediatr (Phila) 2009;48:601- 608
  4. Mandel K, Atkinson S, Barr RD, Pencharz P. Bone morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol 2004;22:1215-1221
  5. Padhye B, Dalla-Pozza L, Little D, Munns C. Incidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL). Cancer Med 2016;5:960-967. 6. te Winkel ML, Pieters R, Hop WC, Roos JC, Bökkerink JP, Leeuw JA, Bruin MC, Kollen WJ, Veerman AJ, de Groot-Kruseman HA, van der Sluis IM, van den Heuvel-Eibrink MM. Bone mineral density at diagnosis determine fracture rates in children with acute lymphoblastic leukemia treated according to the DCOG-ALL9 protocol. Bone 2014;59:223-228
  6. Karol SE, Mattano LA Jr, Yang W, Maloney KW, Smith C, Liu C, Ramsey LB, Fernandez CA, Chang TY, Neale G, Cheng C, Mardis E, Fulton R, Scheet P, San Lucas FA, Larsen EC, Loh ML, Raetz EA, Hunger SP Devidas M, Relling MV. Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood 2016;127:558-564
  7. Kunstreich M, Kummer S, Laws HJ, Borkhardt A, Kuhlen M. Osteonecrosis in children with acute lymphoblastic leukemia. Haematologica 2016;101:1295- 1305
  8. Bürger B, Beier R, Zimmermann M, Beck JD, Reiter A, Schrappe M. Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)-